Cost-Effectiveness of Apixaban for Stroke Prevention in Non-Valvular Atrial Fibrillation in Saudi Arabia

Annals of Saudi Medicine - Saudi Arabia
doi 10.5144/0256-4947.2019.265
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

King Faisal Specialist Hospital and Research Centre

Related search

Pcv84 - Cost-Effectiveness Analysis of Apixaban Versus Edoxaban for Stroke Prevention in Non-Valvular Atrial Fibrillation Spanish Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv75 - An Updated Cost-Effectiveness Pairwise Analysis of Apixaban and Warfarin for Stroke Prevention in Patients With Non- Valvular Atrial Fibrillation in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation – A Multinational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2012English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

PCV48 Systematic Review of Cost-Effectiveness Models for Pharmacologic Stroke Prevention in Atrial Fibrillation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pcv42 - A Pharmacoeconomic Analysis of the Use of Apixaban for the Prevention of Stroke and Systemic Embolism in Russian Patients With Non-Valvular Atrial Fibrillation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PCV56 Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation Under the Private and Public Health Care System in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Estimating the Lifetime Clinical Risk/Benefits of Apixaban Versus Edoxaban in Non-Valvular Atrial Fibrillation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy